Coral Laboratories Ltd () News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 476417,
    "name": "Coral Labs.",
    "stock_name": "Coral Labs.",
    "full_name": "Coral Laboratories Ltd",
    "name_url": "stocks-analysis/coral-labs",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "460.65",
    "chg": -4.35,
    "chgp": "-0.94%",
    "dir": -1,
    "prev_price": "465.00",
    "mcapval": "163.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 524506,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE683E01017",
    "curr_date": "Feb 03",
    "curr_time": "",
    "bse_nse_vol": "2.23 k",
    "exc_status": "Active",
    "traded_date": "Feb 03, 2026",
    "traded_date_str": "2026 02 03",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://uat-researchintel.adityabirlamoney.com/ABML-Landingstocks-analysis/coral-labs-476417-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Coral Labs. Sees Revision in Market Evaluation Amidst Challenging Financial Trends",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/coral-labs-upgraded-from-strong-sell-to-sell-by-marketsmojo-on-27-oct-2025-3746329",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/CoralLabs_mojoScore_3746329.png",
        "date": "2025-12-04 11:08:46",
        "description": "Coral Labs., a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting recent shifts in its financial and technical outlook. This adjustment follows a detailed reassessment of the company’s quality, valuation, financial trends, and technical indicators, set against a backdrop of subdued market performance and sector dynamics."
      },
      {
        "title": "Why is Coral Labs. falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-coral-labs-fallingrising-3744950",
        "imagepath": "",
        "date": "2025-12-04 00:43:55",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Recent Price Movement and Market Comparison</strong></p>\n<p>Coral Laboratories’ share price has been under pressure, registering a loss of 3.56% over the past week compared to a modest 0.59% decline in the Sensex. The divergence becomes more pronounced over the last month, with the stock falling 4.51% while the Sensex gained 1.34%. Year-to-date figures reveal a stark contrast: Coral Labs has declined by 38.05%, whereas the Sensex has appreciated by 8.92%. Over the last year, the stock’s performance has been even more subdued, down 41.00% against the Sensex’s 5.27% rise. These figures highlight a sustained period of underperformance relative to the benchmark index.</p>\n<p>Despite this, the company’s longer-term returns over three and five years remain positive, with gains of 48.98% and 48.13%..."
      },
      {
        "title": "Coral Laboratories Q2 FY26: Sharp Revenue Decline Raises Concerns Despite Margin Recovery",
        "link": "https://www.marketsmojo.com/news/result-analysis/coral-laboratories-q2-fy26-sharp-revenue-decline-raises-concerns-despite-margin-recovery-3718966",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/CoralLaboratori_quaterlyResult_3718966.png",
        "date": "2025-11-18 16:59:45",
        "description": "Coral Laboratories Ltd., a micro-cap pharmaceutical company with a market capitalisation of ₹178.00 crores, reported concerning quarterly results for Q2 FY26, with net profit standing at ₹5.82 crores, representing a sequential increase of 127.34% from Q1 FY26's ₹2.56 crores, but a year-on-year decline of 8.78% from ₹6.38 crores in Q2 FY25. The stock has underperformed significantly over the past year, declining 34.70% whilst the Sensex gained 9.48%, resulting in a negative alpha of 44.18 percentage points."
      },
      {
        "title": "Is Coral Labs. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-coral-labs-overvalued-or-undervalued-3709750",
        "imagepath": "",
        "date": "2025-11-18 08:20:34",
        "description": "As of 17 November 2025, Coral Labs has moved from a very attractive to an attractive valuation grade. The company is currently considered undervalued based on its financial metrics. Key ratios include a PE ratio of 10.25, an EV to EBIT of 5.62, and a Price to Book Value of 0.85, which all suggest a favorable valuation relative to its peers.\n\nIn comparison to its industry peers, Coral Labs stands out with a significantly lower PE ratio than Sun Pharma (36.69) and Divi's Lab (69.78), both classified as expensive. Additionally, Coral Labs' EV to EBITDA of 4.95 is also more attractive than the industry average, reinforcing its undervalued status. Despite a challenging year with a stock return of -40.17%, the company's valuation metrics indicate potential for recovery and growth compared to the Sensex...."
      },
      {
        "title": "How has been the historical performance of Coral Labs.?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-coral-labs-3703296",
        "imagepath": "",
        "date": "2025-11-14 23:54:07",
        "description": "Answer:\nThe historical performance of Coral Labs shows a significant upward trend in net sales and profitability over the past few years.\n\nBreakdown:\nCoral Labs has demonstrated a strong growth trajectory in net sales, increasing from 78.12 Cr in March 2023 to 115.01 Cr in March 2025. This growth is reflected in the total operating income, which also rose from 78.12 Cr in March 2023 to 115.01 Cr in March 2025. The company's operating profit (PBDIT) excluding other income surged from 3.81 Cr in March 2023 to 26.24 Cr in March 2025, indicating improved operational efficiency. Profit before tax followed a similar trend, climbing from 8.23 Cr in March 2023 to 32.47 Cr in March 2025, while profit after tax increased from 6.45 Cr to 24.16 Cr in the same period. The earnings per share (EPS) also saw a substantial rise from 18.07 in March 2023 to 67.68 in March 2025, showcasing enhanced shareholder value. On the ba..."
      },
      {
        "title": "Is Coral Labs. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-coral-labs-overvalued-or-undervalued-3700062",
        "imagepath": "",
        "date": "2025-11-14 08:08:25",
        "description": "As of 13 November 2025, Coral Labs has moved from an attractive to a very attractive valuation grade. The company is currently undervalued, with a PE ratio of 9.66, a Price to Book Value of 0.89, and an EV to EBITDA of 4.22. These ratios indicate a strong valuation position compared to its peers, particularly when contrasted with Sun Pharma's PE ratio of 36.15 and Divi's Lab's PE ratio of 70.4, both of which are significantly higher.\n\nThe company's financial metrics suggest it is well-positioned within the pharmaceuticals and biotechnology sector. With a ROCE of 24.89% and a PEG ratio of 0.00, Coral Labs demonstrates efficient capital utilization and growth potential. Despite recent stock performance lagging behind the Sensex, particularly with a year-to-date return of -34.52% compared to the Sensex's 8.11%, the underlying fundamentals suggest that Coral Labs is a compelling investment opportunity at its cu..."
      },
      {
        "title": "Is Coral Labs. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-coral-labs-overvalued-or-undervalued-3696048",
        "imagepath": "",
        "date": "2025-11-13 08:09:02",
        "description": "As of 12 November 2025, Coral Labs has moved from a very attractive to an attractive valuation grade. The company is currently considered undervalued. Key ratios include a PE ratio of 10.04, an EV to EBITDA of 4.62, and a Price to Book Value of 0.92, which are significantly lower than many of its peers. For instance, Sun Pharma has a PE ratio of 35.94 and Divi's Lab has a PE ratio of 69.64, both categorized as expensive, indicating that Coral Labs is trading at a more favorable valuation relative to these competitors.\n\nIn addition to the favorable ratios, Coral Labs shows a strong ROCE of 24.89% and ROE of 9.18%, suggesting efficient use of capital. The company's recent stock performance has been mixed, with a year-to-date return of -31.95%, contrasting sharply with the Sensex's positive return of 8.10% over the same period. This underperformance may present a buying opportunity, given the company's solid f..."
      }
    ],
    "total": 134,
    "sid": "476417",
    "stock_news_url": "https://uat-researchintel.adityabirlamoney.com/news/coral-laboratories-476417"
  },
  "announcements": [
    {
      "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
      "datetime": "06-Jan-2026",
      "details": "Please find attached herewith Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations 2018 furnished by M/s. MUF Intime India Private Limited (formerly known as Link Intime India Private Limited) the Registrar and Share Transfer agent of the Company for the quarter ended December 31 2025. You are requested to take the same on record.",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Change in Management",
      "datetime": "30-Dec-2025",
      "details": "Sub: Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirement) Regulations 2015 Reg: Intimation regarding Resignation of Company Secretary and Compliance Officer of the Company In compliance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 (Listing Regulations) we hereby inform you that Mrs. Dhwani Desai has tendered her resignation from the post of Company Secretary and Compliance Officer of the Company to pursue another career opportunity.",
      "source": "BSE"
    },
    {
      "caption": "Closure of Trading Window",
      "datetime": "23-Dec-2025",
      "details": "Dear Sir/Madam This is to inform you that pursuant to SEBI (Prohibition of Insider Trading) Regulations 2015 and as per the Companys Code of Conduct to regulate monitor and report trading by insiders (Code) the Trading Window for dealing in the securities of the Company will be closed for all the Designated Persons and their relatives from Thursday January 01 2026 till 48 (forty eight) hours after declaration of unaudited standalone financial results for the quarter and nine months ended December 31 2025. The trading window shall open after 48 hours of declaration of the said results. The date of the Board meeting to consider inter alia unaudited standalone financial results for the quarter and nine months ended December 31 2025 shall be intimated separately in due course. The same is being informed to the Designated Persons and Connected Persons in accordance with the Code of Conduct. Kindly take the same on your record.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Coral Laboratories Ltd has declared <strong>15%</strong> dividend, ex-date: 19 Sep 25",
          "dt": "2025-09-19",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Coral Labs. Sees Revision in Market Evaluation Amidst Challenging Financial Trends

2025-12-04 11:08:46

Coral Labs., a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting recent shifts in its financial and technical outlook. This adjustment follows a detailed reassessment of the company’s quality, valuation, financial trends, and technical indicators, set against a backdrop of subdued market performance and sector dynamics.

Why is Coral Labs. falling/rising?

2025-12-04 00:43:55

Recent Price Movement and Market Comparison Coral Laboratories’ share price has been under pressure, registering a loss of 3.56% over the past week compared to a modest 0.59% decline in the Sensex. The divergence becomes more pronounced over the last month, with the stock falling 4.51% while the Sensex gained 1.34%. Year-to-date figures reveal a stark contrast: Coral Labs has declined by 38.05%, whereas the Sensex has appreciated by 8.92%. Over the last year, the stock’s performance has been even more subdued, down 41.00% against the Sensex’s 5.27% rise. These figures highlight a sustained period of underperformance relative to the benchmark index. Despite this, the company’s longer-term returns over three and five years remain positive, with gains of 48.98% and 48.13%...

Coral Laboratories Q2 FY26: Sharp Revenue Decline Raises Concerns Despite Margin Recovery

2025-11-18 16:59:45

Coral Laboratories Ltd., a micro-cap pharmaceutical company with a market capitalisation of ₹178.00 crores, reported concerning quarterly results for Q2 FY26, with net profit standing at ₹5.82 crores, representing a sequential increase of 127.34% from Q1 FY26's ₹2.56 crores, but a year-on-year decline of 8.78% from ₹6.38 crores in Q2 FY25. The stock has underperformed significantly over the past year, declining 34.70% whilst the Sensex gained 9.48%, resulting in a negative alpha of 44.18 percentage points.

Is Coral Labs. overvalued or undervalued?

2025-11-18 08:20:34

As of 17 November 2025, Coral Labs has moved from a very attractive to an attractive valuation grade. The company is currently considered undervalued based on its financial metrics. Key ratios include a PE ratio of 10.25, an EV to EBIT of 5.62, and a Price to Book Value of 0.85, which all suggest a favorable valuation relative to its peers. In comparison to its industry peers, Coral Labs stands out with a significantly lower PE ratio than Sun Pharma (36.69) and Divi's Lab (69.78), both classified as expensive. Additionally, Coral Labs' EV to EBITDA of 4.95 is also more attractive than the industry average, reinforcing its undervalued status. Despite a challenging year with a stock return of -40.17%, the company's valuation metrics indicate potential for recovery and growth compared to the Sensex....

How has been the historical performance of Coral Labs.?

2025-11-14 23:54:07

Answer: The historical performance of Coral Labs shows a significant upward trend in net sales and profitability over the past few years. Breakdown: Coral Labs has demonstrated a strong growth trajectory in net sales, increasing from 78.12 Cr in March 2023 to 115.01 Cr in March 2025. This growth is reflected in the total operating income, which also rose from 78.12 Cr in March 2023 to 115.01 Cr in March 2025. The company's operating profit (PBDIT) excluding other income surged from 3.81 Cr in March 2023 to 26.24 Cr in March 2025, indicating improved operational efficiency. Profit before tax followed a similar trend, climbing from 8.23 Cr in March 2023 to 32.47 Cr in March 2025, while profit after tax increased from 6.45 Cr to 24.16 Cr in the same period. The earnings per share (EPS) also saw a substantial rise from 18.07 in March 2023 to 67.68 in March 2025, showcasing enhanced shareholder value. On the ba...

Is Coral Labs. overvalued or undervalued?

2025-11-14 08:08:25

As of 13 November 2025, Coral Labs has moved from an attractive to a very attractive valuation grade. The company is currently undervalued, with a PE ratio of 9.66, a Price to Book Value of 0.89, and an EV to EBITDA of 4.22. These ratios indicate a strong valuation position compared to its peers, particularly when contrasted with Sun Pharma's PE ratio of 36.15 and Divi's Lab's PE ratio of 70.4, both of which are significantly higher. The company's financial metrics suggest it is well-positioned within the pharmaceuticals and biotechnology sector. With a ROCE of 24.89% and a PEG ratio of 0.00, Coral Labs demonstrates efficient capital utilization and growth potential. Despite recent stock performance lagging behind the Sensex, particularly with a year-to-date return of -34.52% compared to the Sensex's 8.11%, the underlying fundamentals suggest that Coral Labs is a compelling investment opportunity at its cu...

Is Coral Labs. overvalued or undervalued?

2025-11-13 08:09:02

As of 12 November 2025, Coral Labs has moved from a very attractive to an attractive valuation grade. The company is currently considered undervalued. Key ratios include a PE ratio of 10.04, an EV to EBITDA of 4.62, and a Price to Book Value of 0.92, which are significantly lower than many of its peers. For instance, Sun Pharma has a PE ratio of 35.94 and Divi's Lab has a PE ratio of 69.64, both categorized as expensive, indicating that Coral Labs is trading at a more favorable valuation relative to these competitors. In addition to the favorable ratios, Coral Labs shows a strong ROCE of 24.89% and ROE of 9.18%, suggesting efficient use of capital. The company's recent stock performance has been mixed, with a year-to-date return of -31.95%, contrasting sharply with the Sensex's positive return of 8.10% over the same period. This underperformance may present a buying opportunity, given the company's solid f...

View All News

Announcement

Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018

06-Jan-2026 | Source : BSE

Please find attached herewith Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations 2018 furnished by M/s. MUF Intime India Private Limited (formerly known as Link Intime India Private Limited) the Registrar and Share Transfer agent of the Company for the quarter ended December 31 2025. You are requested to take the same on record.

Announcement under Regulation 30 (LODR)-Change in Management

30-Dec-2025 | Source : BSE

Sub: Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirement) Regulations 2015 Reg: Intimation regarding Resignation of Company Secretary and Compliance Officer of the Company In compliance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 (Listing Regulations) we hereby inform you that Mrs. Dhwani Desai has tendered her resignation from the post of Company Secretary and Compliance Officer of the Company to pursue another career opportunity.

Closure of Trading Window

23-Dec-2025 | Source : BSE

Dear Sir/Madam This is to inform you that pursuant to SEBI (Prohibition of Insider Trading) Regulations 2015 and as per the Companys Code of Conduct to regulate monitor and report trading by insiders (Code) the Trading Window for dealing in the securities of the Company will be closed for all the Designated Persons and their relatives from Thursday January 01 2026 till 48 (forty eight) hours after declaration of unaudited standalone financial results for the quarter and nine months ended December 31 2025. The trading window shall open after 48 hours of declaration of the said results. The date of the Board meeting to consider inter alia unaudited standalone financial results for the quarter and nine months ended December 31 2025 shall be intimated separately in due course. The same is being informed to the Designated Persons and Connected Persons in accordance with the Code of Conduct. Kindly take the same on your record.

Corporate Actions

BOARD MEETING

No Upcoming Board Meetings

DIVIDEND

Coral Laboratories Ltd has declared 15% dividend, ex-date: 19 Sep 25

SPLITS

No Splits history available

BONUS

No Bonus history available

RIGHTS

No Rights history available

Name: MOJO Markets Private Limited (Research Entity) (SEBI Registration No. INH000021942) (CIN:U74900MH2015PTC264951)

Registered & Correspondence Address: Benefice Business House, Office No. 3B, 3rd Floor, C.S. 242, Mathuradas Mills Estate, N.M. Joshi Marg, Tulsi Pipe Road, Lower Parel West, Mumbai- 400013

For queries or grievances, please contact us on support@mojoinfinity.com, Phone : 022-35121239

"Investments in securities market are subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors."